The Institute for Clinical and Economic Review (ICER) has posted the final report “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection”. This report was the subject of deliberation and vote at the public meeting of the California Technology Assessment Forum (CTAF) on Monday, March 10 in San Francisco, California.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
CTAF has long been recognized as one of the leading technology assessment programs in the country. In 2013, CTAF became a core program of the Institute for Clinical and Economic Review, and its approach has now been adapted to broaden stakeholder engagement and improve the application of CTAF products in practice and policy. Learn more »
Attend a Meeting
July 11, 2014
Los Angeles, CA (Sheraton Gateway Hotel at LAX)
CTAF will be examining various treatment options for migraine headaches. The topic is timely given the recent FDA approval of a new hand–held device producing transcranial magnetic stimulation (TMS) for treating migraines. CTAF's review will include evidence on major treatment options (i.e., this new device, various drug regimens, and alternative/ complementary therapies). CTAF’s public deliberation of the evidence will provide clarity and guidance to clinicians, insurers, and patients confronted with decisions on how best to treat migraines.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.